Augustine Therapeutics is a biotechnology company focused on developing first-in-class therapies for rare neuromuscular and neurodegenerative diseases. Founded in 2019 as a spin-off from VIB and KU Leuven, the company's research is centered on the neuroprotective potential of small-molecule HDAC6 inhibitors, targeting diseases like Charcot-Marie-Tooth (CMT) and potentially Amyotrophic Lateral Sclerosis (ALS).

Augustine Therapeutics

ERDINGER Weißbräu is a brewery established in 1886, known for its production of various types of beer, including ERDINGER Weißbier.

ERDINGER Weißbräu

Franziskaner Weissbier is a brewery specializing in the production of wheat beer. It is self-described as part of the Anheuser-Busch InBev group.

Franziskaner Weissbier

Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT), peripheral neuropathies and neurodegenerative disorders. The  company is rooted in the ground-breaking research at VIB and KU Leuven and supported by V-Bio Ventures, PMV, AdBio Partners, VIB New Ventures and Gemma Frisius Fund.  

——— *Disclaimer* ——— 
We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

AdBio partners

V-Bio Ventures

Gemma Frisius Fund

Augustine Therapeutics will be participating to the BIO-EUROPE conference in Munich, Germany on 6-8 November 2023.

Sylvain Celanire, CEO will be available for one-on-one meetings throughout the 3-day conference.

To schedule a meeting, please reach out to us via: https://lnkd.in/gRkjn8M

We will be sharing the latest development on our small molecule HDAC6 inhibitor projects portfolio, including our peripheral-restricted clinical candidate AGT100216 advancing into regulatory development for Charcot-Marie-Tooth disease and Chemotherapy-induced neuropathies, as well as our brain penetrant selective HDAC6 inhibitor program for neurodegenerative diseases, including ALS.

➡ Agenda of Bio-Europe: https://lnkd.in/eXzpc2S2

#lifesciences #bioeurope #biopharma #CIPN  #CMT #ALS #innovation

Meet our new members at Augustine Therapeutics!

We are pleased to announce new appointments to our Leadership team to support the preclinical and clinical development of our peripheral-restricted and centrally acting selective HDAC6 inhibitor pipeline!

Marie Trad joins us as our Chief Medical Officer with extensive experience in clinical and pharmaceutical development in the field of neurology, neuromuscular, and neuropathies, leading global clinical development from early stages throughout the lifecycle of Augustine’s assets development. 

Jonathan van Eyll joins as our Head of Pharmacology. His large experience spanning from in vitro and in vivo translational pharmacology to clinical disease biomarkers of neuroscience therapeutics will strengthen our expertise in accelerating the discovery and development of selective HDAC6 inhibitors for neuromuscular and neurological diseases.

Finally, Cedric Szyndralewiez joins us as Head of Non-Clinical and Early Development, with a strong track record in leading and advancing multiple drug candidates through all stages of preclinical, IND approval to First-in-Patient studies.

We are also expanding our discovery and development platform by joining the Leuven-based Arenberg Accelerator, accessing state-of-the-art laboratories and offices! 

Exciting times for Augustine Therapeutics thanks to the continuous support of our historical investors V-Bio Ventures, PMV, AdBio partners, #VIBNewVentures, VIB, and GEMMA FRISIUS - FONDS K.U.LEUVEN!

To learn more about our exciting new team members, read the full Press Release here: https://lnkd.in/eabJnxNM

#newappointment #biotech #team #healthcare #innovation #pharma #drugdevelopment 

Augustine Therapeutics is proud to sponsor the 2023 Global CMT Research Convention, organized by the US CMT Research Foundation, to be held on September 22nd & 23rd at the Royal Sonesta Boston, Cambridge, MA.

The event is gathering researchers, biotech and pharma companies, investors, and patients to discuss widely the latest research and development towards finding a cure for Charcot-Marie-Tooth patients. This yearly convention enhances the scope and possibilities of research discoveries as a step forward for the people who are living with CMT!

Our CEO, Dr. Sylvain Celanire, will participate as a panel speaker during both Scientific and Patient Community Days:

·       Pushing boundaries in CMT research of early biotech companies – Friday, Sept 22nd afternoon.
 
·       Patient-Powered Perspectives: Biotech Insights on CMT and Collaborating with Patients – Saturday, Sept 23rd afternoon.

We feel extremely thankful to CMT Research Foundation for providing such a global platform. This boosts awareness amongst every individual going through CMT and helps us work with that objective.

Augustine Therapeutics is currently advancing AGT100216 clinical candidate toward a First-in-man clinical trial. AGT100216 is a highly selective, orally bioavailable, and safe HDAC6 inhibitor belonging to a unique and unprecedented chemical class. We have recently communicated at the 2023 PNS conference held in Copenhagen the outstanding preclinical efficacy of AGT100216, not only halting CMT1A disease progression but also significantly reversing disease phenotype and rescuing axonal integrity in a dose-dependent manner after only 4 weeks of low dose oral daily treatment.

Find out details of the event and agenda here: https://lnkd.in/e4uEpnDy

#raredisease #drugdevelopment #healthcareinnovation #research #charcotmarietooth #CMTRF #CMTresearch #CMTconvention

Metric
Company Name	Augustine Therapeutics	ERDINGER Weißbräu	Franziskaner Weissbier
Symbol
MSH ID	COM:AUGUSTINETX	DE:ERDINGER:DE	DE:FRANZISKANER-WEISSBIER
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Goods	Consumer Goods
Industry	Biotechnology	Food & Beverages	Beverages
Country	BE	DE	DE
Stage
Employee Count	14	11
Website	augustinetx.com	de.erdinger.de	franziskaner-weissbier.de
LinkedIn	augustine-therapeutics	privatbrauerei-erdinger-wei%C3%9Fbr%C3%A4u
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic			17.37K
Web Traffic Growth			-0.52
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AUGUSTINETX

Augustine Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue